Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" landscape [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven innovations in medical aesthetics [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will provide its proprietary protein design automation platform and core technologies [1] Group 2: Strategic Objectives - The collaboration aims to break through raw material bottlenecks and upgrade the medical aesthetics business by utilizing Deep Origin's unique protein design platform to address challenges in the design, optimization, and expression of core injectable materials [1] - The initiative is expected to reduce reliance on imported high-end materials, promoting the upgrade of medical aesthetics products towards "high-end and domestically produced" solutions, thereby strengthening market share and brand influence [1] Group 3: R&D Efficiency and Innovation - The partnership will enhance the efficiency of medical aesthetics R&D processes by integrating deep generative models and high-throughput experimental validation systems, which will shorten the early-stage molecular screening cycle and lower development costs [2] - The establishment of the AI R&D company will focus on creating globally innovative raw materials and products, addressing unmet market needs and injecting momentum into the long-term development of the medical aesthetics business [2]

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" innovation track [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven new medical aesthetic product development [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will provide its proprietary protein design automation platform and core technologies [1] Group 2: Technological Advancements - The collaboration aims to create a "dry-wet closed-loop" R&D platform that integrates AI design, high-throughput experimental validation, and data feedback iteration, enhancing the value of the medical aesthetics business [2] - The use of advanced generative models and large language models will shorten the early-stage R&D molecular screening cycle, reduce development costs, and improve the success rate of R&D in the medical aesthetics field [2] Group 3: Market Positioning - The focus on high-end medical aesthetic raw material innovation aims to break the dependency on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetic products towards "high-end and domestically produced" [1] - The collaboration is expected to address unmet market needs in the medical aesthetics sector, injecting momentum into the long-term development of Four Seasons' medical aesthetics business and enhancing its core competitiveness and market value [2]

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" landscape [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven innovations in medical aesthetics [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will contribute its proprietary protein design automation platform and core technologies [1] Group 2: Strategic Objectives - The collaboration aims to break through raw material bottlenecks and upgrade the medical aesthetics business by utilizing Deep Origin's unique protein design platform to address challenges in the design, optimization, and expression of core injectable materials [1] - The initiative is expected to reduce reliance on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetics products towards "high-end and domestically produced" offerings, thereby strengthening market share and brand influence [1] Group 3: R&D Efficiency and Innovation - The partnership will enhance the efficiency of medical aesthetics R&D processes by integrating deep generative models and high-throughput experimental validation systems, which will shorten the early-stage molecular screening cycle and reduce development costs [2] - The establishment of the AI R&D company will focus on globally pioneering raw materials and product development, addressing unmet market needs and injecting momentum into the long-term growth of Four Seasons' medical aesthetics business [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 四環醫藥與深原質藥聯合成立AI研發公司 探索開發AI驅動的新型醫美產品 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為「本集團」）董 事 會（「董事會」）欣 然 宣 佈，為 推 動 人 工 智 慧 技 術（「AI」）在 醫 療 美 容（「醫 美」）產 品 研 發 領 域 的 深 度 應 用 與 產 業 化 落 地，本 集 團 已 與 深 原 質 藥 生 物 科 技（北 京）有 限 公 司（「深原質藥」）簽 署 框 架 協 議。雙 方 將 聯 合 成 立 由 本 集 團 主 導 的AI研 發 公 司，共 同 探 ...

*ST苏吴（维权）"救命稻草"不保，韩国Regen公司单方面宣布解除合作，撤销其孙公司达透医疗对"童 颜针"AestheFill（艾塑菲）在中国大陆的独家代理权。这对本就挣扎在退市边缘的江苏吴中而言，无异 于致命一击。 代理权争夺战：爱美客入主引爆"核弹" 这场风暴早有预兆。今年3月，医美巨头爱美客（300896.SZ）宣布拟收购Regen控股权——而Regen正 是AestheFill的研发方。6月底，随着爱美客完成对Regen的控股并改组董事会，达透医疗便收到一纸 《解约函》。Regen指控达透医疗违规转让业务至母公司江苏吴中美学，且江苏吴中因财务造假、实控 人隐瞒变更等重大违规遭证监会处罚，"严重损害品牌声誉"。 生死攸关：一款产品撑起半壁江山 对江苏吴中而言，失去AestheFill绝非普通业务调整。数据显示： 2024年：AestheFill贡献营收3.26亿元，占总收入20.42%；毛利2.69亿元，占比高达34.80%，助公司净利 润暴增197.97%扭亏为盈。 舆论层面：通过官微痛斥Regen及爱美客"恶意践踏契约精神""打压竞争对手"，更指其"黑化中国企业跨 国形象"，措辞之激烈近年罕见。 ...